Katherine Rielly-Gauvin net worth and biography

Katherine Rielly-Gauvin Biography and Net Worth

Director of Liquidia

Ms. Rielly-Gauvin served as Vice President of Global Commercial Development at AbbVie and brings over 30 years of diverse pharmaceutical industry experience to Liquidia’s Board. At AbbVie, she was responsible for developing the strategic commercial direction of key compounds in the company’s pipeline across core therapeutic areas in Immunology, Oncology, Neuroscience and Specialty. Previously, Ms. Rielly-Gauvin worked in the Johnson & Johnson family of companies in commercial, medical affairs and research capacities, including Vice President and General Manager for the Janssen Commercial CNS organization. She holds a Bachelor of Science in Chemistry from Simmons University and a Master of Business Administration in Economics from Rutgers University.

What is Katherine Rielly-Gauvin's net worth?: The estimated net worth of Katherine Rielly-Gauvin is at least $3.06 million as of August 19th, 2026. Ms. Rielly-Gauvin owns 44,637 shares of Liquidia stock worth more than $3,062,991 as of August 24th. This net worth approximation does not reflect any other investments that Ms. Rielly-Gauvin may own. Learn More about Katherine Rielly-Gauvin's net worth.
How do I contact Katherine Rielly-Gauvin?: The corporate mailing address for Ms. Rielly-Gauvin and other Liquidia executives is 419 DAVIS DRIVE SUITE 100, MORRISVILLE NC, 27560. Liquidia can also be reached via phone at (919) 328-4400 and via email at [email protected]. Learn More on Katherine Rielly-Gauvin's contact information.
Has Katherine Rielly-Gauvin been buying or selling shares of Liquidia?: During the last ninety days, Katherine Rielly-Gauvin has sold $4,087,333.50 of Liquidia stock. Most recently, Katherine Rielly-Gauvin sold 18,393 shares of the business's stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $72.23, for a transaction totalling $1,328,526.39. Following the completion of the sale, the director now directly owns 44,637 shares of the company's stock, valued at $3,224,130.51. Learn More on Katherine Rielly-Gauvin's trading history.
Who are Liquidia's active insiders?: Liquidia's insider roster includes Jason Adair (Chief Business Officer), Stephen Bloch (Director), Dana Boyle (CAO), Roger Jeffs (CEO), Michael Kaseta (CFO), Sanjeev Khindri (Chief Development Officer), Arthur Kirsch (Director), Sarah Krepp (Insider), Paul Manning (Director), Scott Moomaw (Chief Commercial Officer), Katherine Rielly-Gauvin (Director), Rajeev Saggar (Insider), Russell Schundler (General Counsel), and Raman Singh (Director). Learn More on Liquidia's active insiders.
Are insiders buying or selling shares of Liquidia?: In the last year, Liquidia insiders bought shares 1 times. They purchased a total of 5,300 shares worth more than $317,894.00. In the last year, insiders at the sold shares 107 times. They sold a total of 4,087,288 shares worth more than $212,416,232.66. The most recent insider tranaction occured on August, 20th when Director Katherine Rielly-Gauvin sold 18,393 shares worth more than $1,328,526.39. Insiders at Liquidia own 25.6% of the company. Learn More about insider trades at Liquidia.
Information on this page was last updated on 8/20/2026.

Katherine Rielly-Gauvin Insider Trading History at Liquidia

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/20/2026	Sell	18,393	$72.23	$1,328,526.39	44,637
8/19/2026	Sell	36,789	$74.99	$2,758,807.11	44,637

Katherine Rielly-Gauvin Buying and Selling Activity at Liquidia

Liquidia Company Overview

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Today's Range

Now: $68.62

$68.05

$71.13

50 Day Range

MA: $79.29

$68.01

$91.03

2 Week Range

Now: $68.62

$21.15

$93.61

Volume

1,698,913 shs

Average Volume

1,626,062 shs

Market Capitalization

$6.14 billion

P/E Ratio

50.09

Dividend Yield

N/A

Beta

0.58